ECSP099783A - Nuevos compuestos ligandos del receptor de la adenosina a3 - Google Patents

Nuevos compuestos ligandos del receptor de la adenosina a3

Info

Publication number
ECSP099783A
ECSP099783A EC2009009783A ECSP099783A ECSP099783A EC SP099783 A ECSP099783 A EC SP099783A EC 2009009783 A EC2009009783 A EC 2009009783A EC SP099783 A ECSP099783 A EC SP099783A EC SP099783 A ECSP099783 A EC SP099783A
Authority
EC
Ecuador
Prior art keywords
compounds
general formula
adenosine
solvates
isomers
Prior art date
Application number
EC2009009783A
Other languages
English (en)
Inventor
Sandor Batori
Zoltan Kapui
Edit Susan
Tibor Szabo
Katalin Urban-Szabo
Kinga Boer
Geza Timari
Zoltan Szlavik
Endre Mikus
Szeredi Judit Vargane
Michel Finet
Original Assignee
Sanofi Aventis Una Soc Organiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Una Soc Organiz filed Critical Sanofi Aventis Una Soc Organiz
Publication of ECSP099783A publication Critical patent/ECSP099783A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)

Abstract

La presente invención se refiere a los ligandos del receptor de adenosina A3 de fórmula general (I), dentro de ellos los favorables a los antagonistas, a sus sales, solvatos, N-óxidos e isómeros, a las composiciones farmacéuticas que contienen los compuestos de fórmula general (I), sus sales, solvatos, N-óxidos e isómeros, al uso de los compuestos de fórmula general (I), sus sales, solvatos, N-óxidos e isómeros, a la preparación de los compuestos de fórmula general (I), sus sales, solvatos, N-óxidos e isómeros, así como a los nuevos intermediarios de fórmula general (II), (VI), (XI), (XII) y (XV) y a la preparación de ellos.
EC2009009783A 2007-06-07 2009-12-04 Nuevos compuestos ligandos del receptor de la adenosina a3 ECSP099783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700395A HUP0700395A2 (en) 2007-06-07 2007-06-07 Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
PCT/HU2008/000063 WO2008149168A1 (en) 2007-06-07 2008-06-02 Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands

Publications (1)

Publication Number Publication Date
ECSP099783A true ECSP099783A (es) 2010-01-29

Family

ID=89987565

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009783A ECSP099783A (es) 2007-06-07 2009-12-04 Nuevos compuestos ligandos del receptor de la adenosina a3

Country Status (44)

Country Link
US (1) US8338411B2 (es)
EP (1) EP2167470B1 (es)
JP (1) JP5487100B2 (es)
KR (1) KR20100031610A (es)
CN (1) CN101679272B (es)
AR (1) AR066873A1 (es)
AT (1) ATE502016T1 (es)
AU (1) AU2008259534B2 (es)
BR (1) BRPI0812257A2 (es)
CA (1) CA2689612A1 (es)
CL (1) CL2008001648A1 (es)
CO (1) CO6270233A2 (es)
CR (1) CR11171A (es)
CY (1) CY1111644T1 (es)
DE (1) DE602008005589D1 (es)
DK (1) DK2167470T3 (es)
DO (1) DOP2009000276A (es)
EC (1) ECSP099783A (es)
ES (1) ES2363672T3 (es)
GT (1) GT200900301A (es)
HN (1) HN2009003357A (es)
HR (1) HRP20110332T1 (es)
HU (1) HUP0700395A2 (es)
IL (1) IL202471A0 (es)
JO (1) JO2689B1 (es)
MA (1) MA31738B1 (es)
ME (1) ME00958B (es)
MX (1) MX2009013209A (es)
MY (1) MY148654A (es)
NI (1) NI200900210A (es)
NZ (1) NZ581186A (es)
PA (1) PA8782901A1 (es)
PE (1) PE20090325A1 (es)
PL (1) PL2167470T3 (es)
PT (1) PT2167470E (es)
RU (1) RU2489432C2 (es)
SI (1) SI2167470T1 (es)
SV (1) SV2009003420A (es)
TN (1) TN2009000482A1 (es)
TW (1) TWI424998B (es)
UA (1) UA99463C2 (es)
UY (1) UY31130A1 (es)
WO (1) WO2008149168A1 (es)
ZA (1) ZA200908280B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540232T3 (es) 2009-07-08 2015-07-09 Dermira (Canada), Inc. Análogos de TOFA útiles en el tratamiento de trastornos o afecciones dermatológicas
FR3053968A1 (fr) * 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
EP3517113A4 (en) 2016-09-24 2020-07-08 KBP Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A MINERALOCORTICOID RECEPTOR ANTAGONIST AND USE THEREOF
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
KR102653800B1 (ko) 2018-11-30 2024-04-01 머크 샤프 앤드 돔 엘엘씨 아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도
KR20210116488A (ko) 2018-12-20 2021-09-27 인사이트 코포레이션 액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
GR76063B (es) * 1981-04-03 1984-08-03 Roussel Uclaf
ZA836701B (en) * 1982-10-01 1984-10-31 Roussel Uclaf Imidazo(1,2-a)quinolines
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
KR100745307B1 (ko) * 2001-05-31 2007-08-01 사노피-아벤티스 아미노퀴놀린 유도체 및 아데노신 a3 리간드로서의 이의 용도
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
ATE318268T1 (de) 2001-12-21 2006-03-15 Jsw Res Forschungslabor Gmbh Pyrazolyl-substituierte triazolochinoxaline
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
KR20060065662A (ko) * 2003-07-31 2006-06-14 사노피-아벤티스 아미노퀴놀린 유도체 및 아데노신 a3 리간드로서의 이의용도

Also Published As

Publication number Publication date
MA31738B1 (fr) 2010-10-01
AR066873A1 (es) 2009-09-16
GT200900301A (es) 2010-04-22
WO2008149168A1 (en) 2008-12-11
EP2167470A1 (en) 2010-03-31
CL2008001648A1 (es) 2008-10-10
NI200900210A (es) 2010-07-15
CN101679272A (zh) 2010-03-24
NZ581186A (en) 2012-03-30
ATE502016T1 (de) 2011-04-15
ZA200908280B (en) 2010-07-28
UY31130A1 (es) 2009-01-30
PA8782901A1 (es) 2009-01-23
DK2167470T3 (da) 2011-06-27
HU0700395D0 (en) 2007-07-30
HK1138581A1 (en) 2010-08-27
CA2689612A1 (en) 2008-12-11
DOP2009000276A (es) 2010-01-31
JO2689B1 (en) 2013-03-03
SV2009003420A (es) 2010-04-26
US8338411B2 (en) 2012-12-25
UA99463C2 (en) 2012-08-27
WO2008149168A8 (en) 2010-01-07
AU2008259534A1 (en) 2008-12-11
PL2167470T3 (pl) 2011-08-31
ME00958B (me) 2012-06-20
CO6270233A2 (es) 2011-04-20
RU2489432C2 (ru) 2013-08-10
CY1111644T1 (el) 2015-10-07
US20100216786A1 (en) 2010-08-26
BRPI0812257A2 (pt) 2014-12-23
MY148654A (en) 2013-05-15
PE20090325A1 (es) 2009-04-17
KR20100031610A (ko) 2010-03-23
AU2008259534B2 (en) 2012-07-05
SI2167470T1 (sl) 2011-06-30
HUP0700395A2 (en) 2009-03-02
IL202471A0 (en) 2010-06-30
CN101679272B (zh) 2013-02-06
RU2009149518A (ru) 2011-07-20
EP2167470B1 (en) 2011-03-16
TW200914451A (en) 2009-04-01
HRP20110332T1 (hr) 2011-06-30
JP5487100B2 (ja) 2014-05-07
PT2167470E (pt) 2011-05-16
MX2009013209A (es) 2010-04-09
TWI424998B (zh) 2014-02-01
ES2363672T3 (es) 2011-08-11
JP2010529100A (ja) 2010-08-26
DE602008005589D1 (de) 2011-04-28
CR11171A (es) 2010-04-21
TN2009000482A1 (en) 2011-03-31
HN2009003357A (es) 2013-08-12

Similar Documents

Publication Publication Date Title
ECSP099783A (es) Nuevos compuestos ligandos del receptor de la adenosina a3
DOP2009000039A (es) COMPUESTOS DE PIRIDO (2,3-D) PIRIMIDINONA Y SU USO COMO INHIBIDORES DE P13-Ka
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
MX2010001837A (es) Derivados de 4-pirimidinasulfamida.
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
ECSP10010200A (es) Derivados de pirazol como inhibidores de 5-lo
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
ECSP077979A (es) Potenciadores del receptor ampa
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
CU23564A3 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CU20110003A7 (es) Compuestos novedosos activos como antagonistas de receptor muscarínico